Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia.
Agnès LinglartErik Allen ImelMichael P WhyteAnthony A PortaleWolfgang HöglerAnnemieke M BootRaja PadidelaWilliam Van't HoffGary S GottesmanAngel ChenAlison SkrinarMary Scott RobertsThomas O CarpenterPublished in: The Journal of clinical endocrinology and metabolism (2021)
In children with XLH, burosumab administration for 160 weeks improved phosphate homeostasis and rickets and was welltolerated. Long-term safety was consistent with the reported safety profile of burosumab.